MCID: CHR066
MIFTS: 66

Chronic Fatigue Syndrome

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 76 53 55 43 3 15 73
Myalgic Encephalomyelitis 12 76 53
Chronic Fatigue Immune Dysfunction Syndrome 53
Systemic Exertion Intolerance Disease 53
Postviral Fatigue Syndrome 12
Encephalomyelitis, Myalgic 76
Fatigue Syndrome, Chronic 44
Myalgic Encephalitis 12
Chronic Fatigue 6
Cfs 12

Classifications:



Summaries for Chronic Fatigue Syndrome

MedlinePlus : 43 What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What are the symptoms of chronic fatigue syndrome? CFS symptoms can include Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. Who gets chronic fatigue syndrome? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What causes chronic fatigue syndrome? Scientists don't know what causes CFS. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. How is chronic fatigue syndrome diagnosed? CFS can be difficult to diagnose. There are no tests for it, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including Asking about your health history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine or other tests What are the treatments for chronic fatigue syndrome? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems, and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to chronic active epstein-barr virus infection and irritable bowel syndrome, and has symptoms including back pain, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Dopamine and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include testes, lymph node and brain, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 53 Chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials. There is debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome. There is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions.

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 76 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 chronic active epstein-barr virus infection 32.2 IL10 IL2 TGFB1
2 irritable bowel syndrome 32.0 CRH IL10 SLC6A4 TNF
3 fibromyalgia 31.1 COMT CRH IGF1 IL6 SLC6A4
4 generalized anxiety disorder 30.2 HTR1A MAOA SLC6A4
5 depression 30.1 CRH HTR1A MAOA NR3C1 SLC6A4 TPH2
6 alexithymia 30.1 COMT HTR1A IL6 SLC6A4
7 anorexia nervosa 30.1 COMT CRH IGF1 POMC SLC6A4
8 lyme disease 30.0 IL1B IL6 TNF
9 q fever 29.9 IL10 IL1B TNF
10 sleep apnea 29.8 IGF1 IL6 TNF
11 juvenile rheumatoid arthritis 29.7 IL1B IL6 TNF
12 personality disorder 29.7 COMT HTR1A MAOA SLC6A4 TPH2
13 arthritis 29.6 IL10 IL1B IL6 TNF
14 rheumatic disease 29.6 IL10 IL1B TNF
15 multiple sclerosis 29.5 IL10 IL1B IL2 IL6 TNF
16 arteries, anomalies of 29.5 IL1B IL6 TNF
17 attention deficit-hyperactivity disorder 29.5 COMT HTR1A MAOA SLC6A4 TPH2
18 post-traumatic stress disorder 29.3 COMT CRH IL1B MAOA NR3C1 SLC6A4
19 colitis 29.3 IL10 IL1B IL2 IL6 TNF
20 anxiety 29.2 COMT CRH HTR1A MAOA NR3C1 SLC6A4
21 gastrointestinal system disease 29.2 CRH IL10 IL1B IL6 TNF
22 ulcerative colitis 29.1 IL10 IL1B IL2 IL6 TNF
23 prostatitis 29.0 IL10 IL1B IL2 IL6 TGFB1 TNF
24 rheumatoid arthritis 28.5 IL10 IL1B IL2 IL6 TGFB1 TNF
25 bipolar disorder 28.1 COMT CRH HTR1A IGF1 MAOA NR3C1
26 inflammatory bowel disease 27.8 IL10 IL1B IL2 IL6 NR3C1 TGFB1
27 major depressive disorder 26.8 COMT CRH HTR1A IL1B IL6 MAOA
28 chronic pain 11.1
29 nelson syndrome 10.9 CRH NR3C1 POMC
30 acth-secreting pituitary adenoma 10.9 CRH NR3C1 POMC
31 acidophil adenoma 10.9 IGF1 POMC
32 adrenal cortex disease 10.9 CRH NR3C1 POMC
33 adrenal gland disease 10.9 CRH NR3C1 POMC
34 ross river fever 10.9 COMT IL10
35 adrenal gland hyperfunction 10.8 CRH NR3C1 POMC
36 acute adrenal insufficiency 10.8 IL6 POMC
37 atypical depressive disorder 10.8 CRH MAOA SLC6A4
38 sheehan syndrome 10.8 CRH IGF1 POMC
39 pituitary infarct 10.8 IGF1 POMC
40 corticosteroid-binding globulin deficiency 10.8
41 persian gulf syndrome 10.8
42 fasting hypoglycemia 10.8 CRH IGF1 POMC
43 persistent fetal circulation syndrome 10.7 CRH IGF1 POMC
44 endocrine organ benign neoplasm 10.7 CRH IGF1 POMC
45 antisocial personality disorder 10.7 COMT MAOA SLC6A4
46 oral tuberculosis 10.7 IL2 TNF
47 drug dependence 10.7 CRH POMC SLC6A4
48 pituitary gland disease 10.7 CRH IGF1 POMC
49 premature ejaculation 10.7 COMT HTR1A SLC6A4
50 gonadal disease 10.7 CRH IGF1 POMC

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


back pain, fatigue, fever, (non-specific) malaise and fatigue, muscle cramp, muscle rigidity, muscle spasticity, pruritus, sciatica, muscle weakness, myalgia, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 PDCD2 TGFB1 EIF2AK2 TNF IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 PDCD2 TGFB1 EIF2AK2 TNF IL10 IL1B
3 Decreased viability with paclitaxel GR00179-A-1 9.35 TGFB1 IGF1 IL10
4 Decreased viability with paclitaxel GR00179-A-2 9.35 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.35 TGFB1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 SLC6A4 POMC MAOA NR3C1 TPH2 SUN2
2 homeostasis/metabolism MP:0005376 10.43 SLC6A4 POMC MAOA NR3C1 TPH2 SUN2
3 cardiovascular system MP:0005385 10.42 SLC6A4 POMC MAOA NR3C1 TNF TGFB1
4 growth/size/body region MP:0005378 10.39 PDCD2 POMC NR3C1 TPH2 SLC6A4 SUN2
5 cellular MP:0005384 10.35 POMC NR3C1 RNASEL TGFB1 SUN2 TNF
6 hematopoietic system MP:0005397 10.35 POMC NR3C1 RNASEL TNF TGFB1 EIF2AK2
7 endocrine/exocrine gland MP:0005379 10.34 SLC6A4 POMC NR3C1 RNASEL TNF TGFB1
8 mortality/aging MP:0010768 10.33 PDCD2 SLC6A4 POMC NR3C1 TPH2 SUN2
9 immune system MP:0005387 10.32 POMC NR3C1 RNASEL TNF TGFB1 EIF2AK2
10 integument MP:0010771 10.31 PDCD2 POMC NR3C1 SLC6A4 TNF TGFB1
11 nervous system MP:0003631 10.27 POMC MAOA NR3C1 SLC6A4 TNF SUN2
12 adipose tissue MP:0005375 10.19 POMC NR3C1 TNF TGFB1 TPH2 IGF1
13 liver/biliary system MP:0005370 10.08 POMC NR3C1 TGFB1 TNF CRH IL6
14 neoplasm MP:0002006 10.06 POMC TNF TGFB1 EIF2AK2 IGF1 IL2
15 muscle MP:0005369 10.03 NR3C1 TGFB1 SLC6A4 SUN2 TNF IGF1
16 no phenotypic analysis MP:0003012 9.92 POMC NR3C1 TNF TPH2 CRH HTR1A
17 reproductive system MP:0005389 9.81 NR3C1 TGFB1 SUN2 TNF IGF1 COMT
18 renal/urinary system MP:0005367 9.8 NR3C1 IL6 POMC TGFB1 IGF1 CRH
19 respiratory system MP:0005388 9.65 NR3C1 TPH2 TNF TGFB1 COMT IGF1
20 skeleton MP:0005390 9.28 NR3C1 PDCD2 IL6 TGFB1 TNF IGF1

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Sodium oxybate Approved Phase 4 502-85-2 5360545
4
Iron Approved Phase 4 7439-89-6 23925
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9 tannic acid Approved, Nutraceutical Phase 4
10 Central Nervous System Depressants Phase 4,Not Applicable
11 Adjuvants, Anesthesia Phase 4,Phase 1
12 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
13 Central Nervous System Stimulants Phase 4,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
16 Anesthetics Phase 4,Phase 1
17 Anesthetics, General Phase 4
18 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
19 Anesthetics, Intravenous Phase 4
20 Dopamine Agents Phase 4,Phase 2,Phase 3
21 Dopamine Uptake Inhibitors Phase 4,Phase 2
22 Ergocalciferols Phase 4
23 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
24 Bone Density Conservation Agents Phase 4
25 Sildenafil Citrate Phase 4 171599-83-0
26 Vasodilator Agents Phase 4,Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Phosphodiesterase Inhibitors Phase 4
30 Lisdexamfetamine Dimesylate Phase 4
31 Ferric Compounds Phase 4
32 Hematinics Phase 4
33 Vitamin D2 Nutraceutical Phase 4
34 Calciferol Nutraceutical Phase 4
35 Citrate Nutraceutical Phase 4
36
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
37
Norepinephrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 51-41-2 439260
38
Vitamin C Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Not Applicable 50-81-7 5785 54670067
39
Serine Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 56-45-1 5951
40
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Not Applicable 303-98-0 5281915
41 Antibodies Phase 3,Phase 2,Phase 1
42 Immunoglobulins Phase 3,Phase 2,Phase 1
43 Antidepressive Agents Phase 2, Phase 3,Phase 3,Not Applicable
44 Anti-Infective Agents Phase 3,Phase 1,Phase 2
45 Antioxidants Phase 2, Phase 3,Not Applicable
46 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable
47 Psychotropic Drugs Phase 2, Phase 3,Phase 3,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 2
49 Antiviral Agents Phase 3,Phase 1,Phase 2
50 Ubiquinone Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
5 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
6 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
9 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
10 B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
11 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
12 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
13 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
14 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
15 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3 Ampligen
16 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
17 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
18 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
19 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
20 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
21 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
22 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Unknown status NCT02924831 Phase 2
23 The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
24 Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
25 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Unknown status NCT02444091 Phase 2 Cyclophosphamide
26 Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) Unknown status NCT00478465 Phase 1, Phase 2 valganciclovir
27 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
28 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Completed NCT01512342 Phase 2
29 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Completed NCT01156909 Phase 2 Rituximab
30 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
31 Acupressure for Post-Treatment Cancer Fatigue Completed NCT00959998 Phase 2
32 Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain Completed NCT00524420 Phase 2
33 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) Completed NCT00810368 Phase 2 Carnosine;Placebo
34 Creatine Supplementation in Chronic Fatigue Syndrome Active, not recruiting NCT02374112 Phase 2
35 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Terminated NCT01730495 Phase 2 Etanercept
36 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Terminated NCT01156922 Phase 2 Rituximab
37 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
38 Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
39 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
40 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects Recruiting NCT02955420 Phase 1 BC 007;NaCl 0.9 %
41 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
42 Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome Unknown status NCT01893619
43 Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome Unknown status NCT01534130 Not Applicable
44 The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Population Unknown status NCT02082730 Not Applicable
45 Use of a Monitor in ME/CFS Unknown status NCT01908036
46 A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng Unknown status NCT02847845 Not Applicable
47 Genetics of Fibromyalgia Unknown status NCT00071162
48 Neuroscience Education on Osteoarthritis Unknown status NCT02246088 Not Applicable
49 Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes Unknown status NCT01154647 Not Applicable citalopram;1 ml 0.9 % NaCl
50 Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE) Unknown status NCT01460680

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

41
Testes, Lymph Node, Brain, Pituitary, B Cells, Prostate, Amygdala

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 868)
# Title Authors Year
1
Operationalizing Substantial Reduction in Functioning Among Young Adults with Chronic Fatigue Syndrome. ( 29872989 )
2018
2
Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. ( 29968805 )
2018
3
The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. ( 29759891 )
2018
4
Poor self-reported sleep quality and health-related quality of life in patients with chronic fatigue syndrome/myalgic encephalomyelitis. ( 29770505 )
2018
5
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. ( 29409505 )
2018
6
Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. ( 29969498 )
2018
7
Rethinking childhood adversity in chronic fatigue syndrome. ( 29392095 )
2018
8
Hair and salivary cortisol in a cohort of women with chronic fatigue syndrome. ( 29807037 )
2018
9
Efficacy of web-based cognitive-behavioural therapy for chronic fatigue syndrome: randomised controlled trial. ( 29436329 )
2018
10
The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). ( 29588088 )
2018
11
A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications. ( 29411266 )
2018
12
Cardiovascular characteristics of chronic fatigue syndrome. ( 29399336 )
2018
13
Severe eosinophilic colitis caused by neuropathic agents in a patient with chronic fatigue syndrome and functional abdominal pain: case report and review of the literature. ( 29890559 )
2018
14
Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). ( 29867995 )
2018
15
Glucocorticoid receptor DNA methylation and childhood trauma in chronic fatigue syndrome patients. ( 29275786 )
2018
16
Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. ( 29855991 )
2018
17
Deconstructing post-exertional malaise in myalgic encephalomyelitis/ chronic fatigue syndrome: A patient-centered, cross-sectional survey. ( 29856774 )
2018
18
Effects of a short-term aquatic exercise intervention on symptoms and exercise capacity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis: a pilot study. ( 29923110 )
2018
19
Structural brain changes versus self-report: machine-learning classification of chronic fatigue syndrome patients. ( 29846797 )
2018
20
Cortical hypoactivation during resting EEG suggests central nervous system pathology in patients with chronic fatigue syndrome. ( 29802861 )
2018
21
A reboot for chronic fatigue syndrome research. ( 29300036 )
2018
22
Chronic fatigue syndrome (CFS/ME) symptom-based phenotypes and 1-year treatment outcomes in two clinical cohorts of adult patients in the UK and The Netherlands. ( 29275782 )
2018
23
Chronic fatigue syndrome in Chinese middle-school students. ( 29369204 )
2018
24
Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 29426834 )
2018
25
Dutch Health Council Advisory Report on Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: Taking the Wrong Turn. ( 29772739 )
2018
26
Correction: Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. ( 29420633 )
2018
27
Circadian rhythm abnormalities and autonomic dysfunction in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ( 29874259 )
2018
28
Myalgic encephalomyelitis/chronic fatigue syndrome and the biopsychosocial model: a review of patient harm and distress in the medical encounter. ( 29929450 )
2018
29
Recent insights into 3 underrecognized conditions: Myalgic encephalomyelitis-chronic fatigue syndrome, fibromyalgia, and environmental sensitivities-multiple chemical sensitivity. ( 29898928 )
2018
30
Eukaryotes in the gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome. ( 29375937 )
2018
31
Improvement of severe myalgic encephalomyelitis/chronic fatigue syndrome symptoms following surgical treatment of cervical spinal stenosis. ( 29391028 )
2018
32
Cerebral Blood Flow and Heart Rate Variability in Chronic Fatigue Syndrome: A Randomized Cross-Over Study. ( 29357332 )
2018
33
Childhood sleep and adolescent chronic fatigue syndrome (CFS/ME): evidence of associations in a UK birth cohort. ( 29773208 )
2018
34
On chronic fatigue syndrome and nosological categories. ( 29417255 )
2018
35
Two-Year Follow-Up of Impaired Range of Motion in Chronic Fatigue Syndrome. ( 29866593 )
2018
36
Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review and meta-ethnography of qualitative studies. ( 28087544 )
2017
37
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. ( 28059425 )
2017
38
Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. ( 28441964 )
2017
39
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study. ( 28302133 )
2017
40
Elevated brain natriuretic peptide levels in chronic fatigue syndrome associate with cardiac dysfunction: a case control study. ( 29344367 )
2017
41
Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. ( 28129747 )
2017
42
Chronic fatigue syndrome and idiopathic intracranial hypertension: Different manifestations of the same disorder of intracranial pressure? ( 28735654 )
2017
43
Differentiating Multiple Sclerosis from Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. ( 29430570 )
2017
44
PACE trial claims for recovery in myalgic encephalomyelitis/chronic fatigue syndrome - true or false? It's time for an independent review of the methodology and results. ( 28805522 )
2017
45
Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome. ( 28805529 )
2017
46
Elevations of Ventricular Lactate Levels Occur in Both Chronic Fatigue Syndrome and Fibromyalgia. ( 29308330 )
2017
47
Bias, misleading information and lack of respect for alternative views have distorted perceptions of myalgic encephalomyelitis/chronic fatigue syndrome and its treatment. ( 28805527 )
2017
48
Inflammation correlates with symptoms in chronic fatigue syndrome. ( 28811366 )
2017
49
Cognitive and behavioral coping in people with Chronic fatigue syndrome: An exploratory study searching for intervention targets for depressive symptoms. ( 28810458 )
2017
50
How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? ( 28810428 )
2017

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 9355: 9355
2 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 9355: 9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 EIF2AK2 IL10 IL1B IL2 IL6 MAOA
2
Show member pathways
13.32 IGF1 IL10 IL1B IL2 IL6 TGFB1
3
Show member pathways
13.06 IL10 IL1B IL2 IL6 RNASEL TGFB1
4
Show member pathways
12.91 IL10 IL1B IL2 IL6 TGFB1 TNF
5
Show member pathways
12.84 EIF2AK2 IL1B IL2 IL6 RNASEL TNF
6
Show member pathways
12.74 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
7
Show member pathways
12.7 IL10 IL1B IL2 IL6 RNASEL TNF
8
Show member pathways
12.64 EIF2AK2 IL10 IL1B IL2 IL6 TNF
9 12.61 IL10 IL1B IL2 RNASEL TNF
10
Show member pathways
12.5 IL10 IL1B IL2 IL6 TGFB1 TNF
11
Show member pathways
12.48 IL10 IL1B IL2 IL6 TGFB1 TNF
12 12.43 IL2 IL6 TGFB1 TNF
13
Show member pathways
12.35 IL1B IL2 IL6 TNF
15 12.29 IL10 IL1B IL6 TGFB1 TNF
16
Show member pathways
12.28 IL10 IL1B TGFB1 TNF
17
Show member pathways
12.27 IL10 IL1B IL2 IL6 TNF
18
Show member pathways
12.24 IGF1 IL6 TGFB1 TNF
19
Show member pathways
12.23 IL10 IL1B IL2 IL6 TGFB1 TNF
20
Show member pathways
12.13 IGF1 IL10 IL6 TGFB1
21 12.12 IGF1 IL6 NR3C1 TGFB1 TNF
22
Show member pathways
12.07 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
23 12.06 IL1B IL2 IL6 TGFB1 TNF
24 12.05 IL10 IL2 IL6 TNF
25 12.03 HTR1A MAOA SLC6A4 TPH2
26 11.99 IGF1 IL1B IL6 RNASEL TGFB1
27 11.97 IL1B IL6 TGFB1 TNF
28 11.94 CRH IL2 POMC TGFB1
29 11.91 IL1B IL6 TGFB1 TNF
30 11.9 IL10 IL1B IL6 TGFB1 TNF
31 11.87 IL2 IL6 NR3C1 POMC
32 11.85 IL10 IL1B IL2 TNF
33 11.82 IL10 IL1B IL6 TNF
34 11.76 IL10 IL1B IL6 MAOA POMC TGFB1
35 11.65 IGF1 IL1B IL6 TGFB1 TNF
36
Show member pathways
11.63 IL1B IL2 IL6 NR3C1 TNF
37 11.62 IL1B IL6 TNF
38 11.61 IL10 IL1B IL6 TNF
39 11.6 IL10 IL1B IL2 IL6 TGFB1 TNF
40 11.59 IL1B IL2 TGFB1 TNF
41 11.58 IL2 IL6 TNF
42 11.56 IGF1 IL6 TGFB1
43 11.49 IL10 IL1B IL6 TGFB1 TNF
44 11.49 HTR1A IL10 IL1B IL6 MAOA NR3C1
45 11.42 IGF1 IL1B IL6 NR3C1 TNF
46 11.4 IL10 IL1B IL6 TNF
47 11.39 IL10 IL1B IL6 TNF
48 11.37 IL1B IL6 TNF
49 11.35 IL1B IL6 TNF
50
Show member pathways
11.35 IL1B MAOA SLC6A4 TNF TPH2

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CRH IGF1 IL10 IL1B IL2 IL6
2 extracellular space GO:0005615 9.28 CRH IGF1 IL10 IL1B IL2 IL6

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.99 IGF1 IL1B SUN2 TGFB1
2 positive regulation of cell proliferation GO:0008284 9.98 CRH HTR1A IGF1 IL1B IL2 IL6
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 IGF1 IL6 TGFB1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 IL6 TGFB1 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.88 CRH IL1B IL2 TGFB1 TNF
6 cellular response to organic cyclic compound GO:0071407 9.87 IL1B TGFB1 TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IGF1 IL2 IL6
8 response to estrogen GO:0043627 9.86 COMT CRH TPH2
9 positive regulation of DNA binding transcription factor activity GO:0051091 9.86 IL10 IL1B IL6 TNF
10 positive regulation of T cell proliferation GO:0042102 9.85 IL1B IL2 IL6
11 positive regulation of transcription by RNA polymerase II GO:0045944 9.85 IGF1 IL10 IL1B IL2 IL6 NR3C1
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 IGF1 IL6 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.83 IL1B IL6 TNF
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 EIF2AK2 IL1B TNF
15 negative regulation of fat cell differentiation GO:0045599 9.82 IL6 TGFB1 TNF
16 positive regulation of interferon-gamma production GO:0032729 9.81 IL1B IL2 TNF
17 negative regulation of viral genome replication GO:0045071 9.8 EIF2AK2 RNASEL TNF
18 response to glucocorticoid GO:0051384 9.8 IL10 IL6 TNF TPH2
19 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 EIF2AK2 IL1B IL6 TGFB1 TNF
20 positive regulation of gene expression GO:0010628 9.8 CRH IGF1 IL1B IL6 SLC6A4 TGFB1
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.79 IGF1 IL10 TNF
22 negative regulation of mitotic cell cycle GO:0045930 9.78 IL10 TGFB1 TNF
23 cellular response to dexamethasone stimulus GO:0071549 9.75 CRH NR3C1 TGFB1
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 IL1B TGFB1 TNF
25 response to organic substance GO:0010033 9.72 IGF1 IL10 SLC6A4 TGFB1 TNF
26 positive regulation of interleukin-17 production GO:0032740 9.71 IL2 TGFB1
27 positive regulation of immunoglobulin secretion GO:0051024 9.71 IL2 IL6
28 neurotransmitter catabolic process GO:0042135 9.7 COMT MAOA
29 catecholamine metabolic process GO:0006584 9.7 COMT MAOA
30 positive regulation of regulatory T cell differentiation GO:0045591 9.7 IL2 TGFB1
31 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
32 positive regulation of chemokine production GO:0032722 9.69 EIF2AK2 IL6 TNF
33 dopamine catabolic process GO:0042420 9.68 COMT MAOA
34 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
35 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
36 regulation of establishment of endothelial barrier GO:1903140 9.67 IL1B TNF
37 protein kinase B signaling GO:0043491 9.67 IGF1 IL1B TGFB1 TNF
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 IL10 TNF
39 positive regulation of fever generation GO:0031622 9.65 IL1B TNF
40 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 IL10 IL1B TNF
41 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
42 receptor biosynthetic process GO:0032800 9.6 IL10 TNF
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.59 IL1B TNF
44 positive regulation of mononuclear cell migration GO:0071677 9.58 TGFB1 TNF
45 regulation of signaling receptor activity GO:0010469 9.56 IGF1 IL10 IL1B IL2 IL6 POMC
46 regulation of hematopoietic progenitor cell differentiation GO:1901532 9.55 EIF2AK2 PDCD2
47 regulation of serotonin secretion GO:0014062 9.54 CRH HTR1A
48 cytokine-mediated signaling pathway GO:0019221 9.23 IL10 IL1B IL2 IL6 MAOA POMC
49 positive regulation of transcription, DNA-templated GO:0045893 10.11 IGF1 IL10 IL1B IL6 TGFB1 TNF
50 immune response GO:0006955 10.1 IL10 IL1B IL2 IL6 TNF

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.1 IL10 IL1B IL2 IL6 TGFB1 TNF

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....